Lanean...
FGF19/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib
BACKGROUND: Sorafenib, a multi-kinase inhibitor, is used as a standard therapy for advanced hepatocellular carcinoma (HCC). However, complete remission has not been achieved and the molecular basis of HCC resistance to sorafenib remains largely unknown. Previous studies have shown that fibroblast gr...
Gorde:
| Argitaratua izan da: | J Exp Clin Cancer Res |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BioMed Central
2017
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5223586/ https://ncbi.nlm.nih.gov/pubmed/28069043 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-016-0478-9 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|